clinical trial · NCT07920783
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic DermatitisGLR2053 TabletsPlacebo
brief summary
This is a first-in-human (FIH) study to evaluate the safety, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of GLR2053 in healthy male and female adult participants, and to evaluate the effect of a high-fat meal on the pharmacokinetics of GLR2053.
started
Nov 5, 2026
primary completion
Jul 30, 2027
completion
Nov 9, 2027
last updated
Nov 6, 2026
official title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of GLR2053 Tablets Following Single and Multiple Dose Administration, and the Effect of Food in Healthy Adult Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol